Insulet [PODD] vs Boston Scientific [BSX] Detailed Stock Comparison

Insulet Corporation

NASDAQ
Loading...

Boston Scientific Corporation

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Insulet Corporation wins in 6 metrics, Boston Scientific Corporation wins in 13 metrics, with 0 ties. Boston Scientific Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Insulet Corporation Boston Scientific Corporation Better
P/E Ratio (TTM) 55.27 27.49 Boston Scientific Corporation
Price-to-Book Ratio 8.93 4.02 Boston Scientific Corporation
Debt-to-Equity Ratio 66.18 48.92 Boston Scientific Corporation
PEG Ratio 23.80 0.29 Boston Scientific Corporation
EV/EBITDA 24.51 19.85 Boston Scientific Corporation
Profit Margin (TTM) 9.12% 17.29% Boston Scientific Corporation
Operating Margin (TTM) 18.67% 21.55% Boston Scientific Corporation
EBITDA Margin (TTM) 18.67% 21.55% Boston Scientific Corporation
Return on Equity 18.12% 11.84% Insulet Corporation
Return on Assets (TTM) 9.43% 6.64% Insulet Corporation
Free Cash Flow (TTM) $349.90M $3.40B Boston Scientific Corporation
1-Year Return -50.86% -52.97% Insulet Corporation
Price-to-Sales Ratio (TTM) 5.00 4.74 Boston Scientific Corporation
Enterprise Value $13.83B $107.72B Boston Scientific Corporation
EV/Revenue Ratio 5.11 5.23 Insulet Corporation
Gross Profit Margin (TTM) 72.54% N/A N/A
Revenue per Share (TTM) $39 $14 Insulet Corporation
Earnings per Share (Diluted) $3.48 $2.39 Insulet Corporation
Beta (Stock Volatility) 1.47 0.78 Boston Scientific Corporation
Short % of Float 4.97% 1.58% Boston Scientific Corporation

Insulet Corporation vs Boston Scientific Corporation Stock Performance Analysis

Loading Price Chart...

PODD
BSX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Insulet Corporation-1.04%-2.22%0.46%-34.06%-49.18%-47.64%
Boston Scientific Corporation-0.32%-3.98%-11.24%-33.00%-49.28%-50.63%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Insulet Corporation-50.86%-47.38%-46.64%417.99%674.84%886.17%
Boston Scientific Corporation-52.97%-13.64%9.04%108.58%590.87%133.50%

Performance & Financial Health Analysis: Insulet Corporation vs Boston Scientific Corporation

MetricPODDBSX
Market Information
Market Cap i$13.53B$97.63B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i743,37118,916,072
90 Day Avg. Volume i897,96016,730,711
Last Close$148.14$46.76
52 Week Range$140.63 - $354.88$45.99 - $109.50
% from 52W High-58.26%-57.30%
All-Time High$354.88 (Nov 20, 2025)$109.50 (Sep 09, 2025)
% from All-Time High-58.26%-57.30%
Growth Metrics
Quarterly Revenue Growth0.31%0.12%
Quarterly Earnings Growth0.01%0.99%
Financial Health
Profit Margin (TTM) i0.09%0.17%
Operating Margin (TTM) i0.19%0.22%
Return on Equity (TTM) i0.18%0.12%
Debt to Equity (MRQ) i66.1848.92
Cash & Liquidity
Book Value per Share (MRQ)$21.53$16.34
Cash per Share (MRQ)$10.17$1.32
Operating Cash Flow (TTM) i$569.30M$4.50B
Levered Free Cash Flow (TTM) i$154.90M$10.53B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Insulet Corporation vs Boston Scientific Corporation

MetricPODD (Apr 24, 2026)BSX (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i55.2727.49
Forward P/E i23.8017.29
PEG Ratio i23.800.29
Price to Sales (TTM) i5.004.74
Price to Book (MRQ) i8.934.02
Market Capitalization
Market Capitalization i$13.53B$97.63B
Enterprise Value i$13.83B$107.72B
Enterprise Value Metrics
Enterprise to Revenue i5.115.23
Enterprise to EBITDA i24.5119.85
Risk & Other Metrics
Beta i1.470.78
Book Value per Share (MRQ) i$21.53$16.34

Financial Statements Comparison: Insulet Corporation vs Boston Scientific Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPODD (2025)BSX (2025)
Revenue/Sales i2.71B20.07B
Cost of Goods Sold i768.20M6.22B
COGS % of Revenue i28.4%31.0%
Gross Profit i1.94B13.85B
Gross Margin i71.6%69.0%
Research & Development i301.10M2.05B
Operating Income (EBIT) i473.80M3.97B
Operating Margin i17.5%19.8%
EBITDA i600.70M5.33B
EBITDA Margin i22.2%26.6%
Pre-Tax Income i339.50M3.39B
Pre-Tax Income % of Revenue i12.5%16.9%
Income Tax i92.40M493.00M
Income Tax % of Revenue i3.4%2.5%
Net Income (Profit) i247.10M2.89B
Profit Margin i9.1%14.4%

Balance Sheet & Liquidity Metrics

MetricPODD (2025)BSX (2025)
Cash & Equivalents i716.10M1.97B
Total Current Assets i1.91B8.79B
Total Current Assets % of Revenue i70.7%43.8%
Total Current Liabilities i680.10M5.44B
Total Current Liabilities % of Revenue i25.1%27.1%
Long-Term Debt i930.80M11.14B
Long-Term Debt % of Revenue i34.4%55.5%
Total Shareholders Equity i1.52B24.47B
Retained Earnings i287.40M5.57B
Retained Earnings % of Revenue i10.6%27.8%
Property, Plant & Equipment i00

Cash Flow Statement Comparison

MetricPODD (2025)BSX (2025)
Operating Cash Flow i374.00M4.50B
Operating Cash Flow % of Revenue i13.8%22.4%
Capital Expenditures iN/A-876.00M
Free Cash Flow i349.90M3.40B
FCF Margin i12.9%17.0%
Debt Repayment i-1.21B-2.05B
Common Stock Repurchase i-59.60MN/A

Short Interest & Institutional Ownership Analysis

MetricPODDBSX
Shares Short i3.05M23.53M
Short Ratio i3.131.59
Short % of Float i4.97%1.58%
Shares Outstanding i70.39M1.49B
Float Shares i70.10M1.48B
% Held by Insiders i0.31%0.21%
% Held by Institutions i105.62%95.16%
% Held by Public i-5.93%4.63%

Dividend Analysis & Yield Comparison: Insulet Corporation vs Boston Scientific Corporation

MetricPODDBSX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A